Cargando…

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies

Detalles Bibliográficos
Autores principales:	Adelman, Daphne T., Van Genechten, Dirk, Megret, Clémentine M., Truong Thanh, Xuan-Mai T., Hand, Philippa, Martin, Wendy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999158/ https://www.ncbi.nlm.nih.gov/pubmed/31953807 http://dx.doi.org/10.1007/s12325-020-01226-z

Ejemplares similares

Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2019)

MON-022 Enhancing Patient Care: Co-Creation and Validation of a New and Improved Delivery System for Lanreotide Depot/Autogel and Its Evaluation by US Healthcare Professionals
por: Adelman, Daphne, et al.
Publicado: (2019)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
por: Bevan, J S, et al.
Publicado: (2008)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
por: Caron, Philippe J., et al.
Publicado: (2015)

Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
por: Alvarez-Escola, Cristina, et al.
Publicado: (2015)

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
por: Lucas, T, et al.
Publicado: (2006)

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
por: Dromain, Clarisse, et al.
Publicado: (2021)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
por: Caron, Philippe J., et al.
Publicado: (2014)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014)

Lanreotide Autogel in the Treatment of Persistent Diarrhea following a Total Colectomy
por: Schoeters, Patrick, et al.
Publicado: (2015)

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria
por: Rinke, Anja, et al.
Publicado: (2021)

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
por: Petersenn, Stephan, et al.
Publicado: (2019)

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
por: An, Zhenmei, et al.
Publicado: (2020)

Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
por: Zafra, Gema Marín, et al.
Publicado: (2016)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

THU062 PRESTO 3: A Simulated-use Study Assessing Preferences Of Nurses In The USA And Europe Between Two Lanreotide Syringes (Somatuline Autogel Vs Pharmathen)
por: Williams, Jessica, et al.
Publicado: (2023)

Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
por: Aerts, Maridi, et al.
Publicado: (2017)

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional
por: Johanson, Viktor, et al.
Publicado: (2012)

Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study
por: Ito, Tetsuhide, et al.
Publicado: (2020)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
por: Martín-Richard, Marta, et al.
Publicado: (2013)

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
por: Salvatori, Roberto, et al.
Publicado: (2009)

Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study
por: Paulson, Scott, et al.
Publicado: (2022)

LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors – results of interim analysis
por: Orlewska, Ewa, et al.
Publicado: (2014)

A New Approach to Supramolecular Structure Determination in Pharmaceutical Preparation of Self-Assembling Peptides: A Case Study of Lanreotide Autogel
por: Grimaldi, Manuela, et al.
Publicado: (2022)

Primary treatment of acromegaly with high-dose lanreotide: a case series
por: Wuster, Christian, et al.
Publicado: (2010)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b91v3vvn56punttqmp6i7bugh9